Adverse drug reactions
Enhancing postmarketing surveillance: continuing challenges
Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients
Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation
Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation
The pharmacokinetics and safety of darapladib in subjects with severe renal impairment
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers
Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6
Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study
Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria
Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study
Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study
Treatment of spontaneous preterm labour with retosiban: a phase 2 proof-of-concept study
NSAIDs and spontaneous abortions – true effect or an indication bias?
Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case–control study
Mirabegron
Vemurafenib/dabrafenib and trametinib
The impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysis
Phenoconversion and therapeutic drug monitoring
Indication bias or protopathic bias?
Reply to ‘Indication bias or protopathic bias?’
High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19* 17 /* 17 genotype
The burden of adverse drug events
Adverse drug reactions in neonates and infants: a population-tailored approach is needed
Adverse drug reactions in special populations – the elderly
Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review
Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey
Quality of life in children with adverse drug reactions: a narrative and systematic review
An overview on adverse drug reactions to traditional Chinese medicines
Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review
Adverse drug reactions – examples of detection of rare events using databases
The potential of translational bioinformatics approaches for pharmacology research
Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials
Systematic review on the prevalence, frequency and comparative value of adverse events data in social media
In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology
Drug-induced acute kidney injury in children
Social media and pharmacovigilance: A review of the opportunities and challenges
Erratum